Life Biosciences Announces Closing of $50 Million Series B Financing Round

BOSTON, Jan. 15, 2019 — Life Biosciences has announced the closing of a Series B financing round of $50 million, according to Tristan Edwards, chief executive officer and co-founder. The Company initially targeted a $25 million round but upsized to meet investor demand. The proceeds of the investment will be used to continue Life Biosciences’ and its Daughter Companies’ research and development activities in potential therapeutics to combat age-related decline, and related purposes.

“We are excited by this investor response to our Series B, and the validation it represents,” said Edwards. “The range of investors in this round includes individuals, family trusts, and other professional investors. We believe this response recognizes the power of our teams and science, and the progress we are making in addressing the pathways of aging.”

– Life Biosciences Overview –

Life Biosciences is dedicated to tackling the eight pathways of age-related decline (ARD) as the cause of the systemic breakdown of the body, rather than a series of isolated symptoms, events and conditions. The company brings together the world’s leading scientists and researchers to increase healthspans and reduce disease for everyone, including companion animals.

Life Biosciences was co-founded in 2017 by renowned scientists and Tristan Edwards, who developed its innovative structure as Chapter Two in his life after a highly successful career as a global institutional investor working across all asset classes.  There are six Daughter companies working independently and together within the Life Biosciences research environment.

The company also recently announced a significant investment in Prana, a publicly traded Australian biotech company, and the acquisition of Lua, Life Biosciences’ HIPAA-compliant medical technology platform. Life Biosciences provides Daughter companies with the resources required to maximize human potential, including Life Lua’s data and communications platform, experienced management, drug development experience, and a 24,000-square-foot, state-of-the-art vivarium, robotics and drug screening facility in Cambridge, Mass (USA), in addition to laboratories and offices on four continents.

Co-founded in 2017 by Tristan Edwards and renowned scientists, Life Biosciences is a company addressing the eight pathways of age-related decline (ARD) as a systemic breakdown of the body, not a series of isolated symptoms and conditions. It has established Daughter companies around the world to independently and collaboratively attack these pathways through pioneering research and product development. The company provides Daughter companies with the full resources of Life Lua’s data and communications platform; LifeLab, its 24,000- square-foot, state-of-the-art research facility that includes a vivarium, robotics, and drug screening capabilities. Life Biosciences seeks to increase healthspans for everyone, including companion animals.

For more information on Life Biosciences, please visit
Press Contact: